

Atty. Docket No.:

20200/2093D

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Kreutzer, et al.

Serial No.:

10/612,179

Filed:

July 2, 2003

Entitled:

METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

Group Art Unit:

1645

Conf. No.:

5239

## CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. Information Disclosure Statement;
- 2. Form PTO-1449;
- 3. Copies of Cited References; and
- 4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 20200/2093D. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: January 8, 2004

Name: Barbara A. Gyure Registration No.: 34,614 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.:

20200/2093D

**PATENT** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Kreutzer, et al.

Serial No.:

10/612,179

Filed:

July 2, 2003

Entitled:

METHOD AND MEDICAMENT

FOR INHIBITING THE

EXPRESSION OF A GIVEN GENE

Examiner:

Not Yet Assigned

Group Art Unit:

1645

Conf. No.:

5239

### CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A copy of a portion of the cited documents were submitted to the U.S. Patent and Trademark Office in the parent application, U.S. Serial No. 09/889,802. Copies of the documents in the list which were not submitted with the parent application are enclosed for the Examiner's convenience. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: January 8, 2004

Respectfully submitted,

Name: Barbara A. Gyure Registration No.: 34,614 Palmer & Dodge LLP

Babacill. Dyne

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

P L COOLS

USPTO Form 1449 Serial No. Attorney Docket No. Patent and Trademark Office 10/612,179 20200/2093D INFORMATION DISCLOSURE STATEMENT Applicant(s):. Kreutzer et al. Filing Date: July 2, 2003 Group: 1645 **U.S. PATENT DOCUMENTS** Examiner Patent No. Date Name Class Subclass Filing Date Initial (if appropriate) 2003/0198627 A1 1. Oct. 23, 2003 424 93.21 Arts, et al. Aug. 23, 2002 2. 2003/0190635 A1 Oct. 9, 2003 McSwiggen 435 6 Jul. 25, 2002 3. 2003/0180756 A1 Sep. 25, 2003 Shi, et al. 435 6 Nov. 21, 2002 4. 2003/0176671 A1 Sep. 18, 2003 Reed, et al. 536 23.1 Feb. 7, 2002 5. 2003/0157030 A1 Aug. 21, 2003 424 46 Davis, et al. Nov. 4, 2002 6. Aug. 7, 2003 6 2003/0148341 A1 Sin, et al. 435 Nov. 5, 2002 7. 2003/0143732 A1 Jul. 31, 2003 Fosnaugh, et al. 435 325 Aug. 20, 2002 8. 2003/0125281 A1 Jul. 3, 2003 Lewis, et al. 514 44 May 28, 2002 9. 2003/0108923 A1 Jun. 12, 2003 Tuschl, et al. 435 6 Sep. 26, 2002 10. 2002/0086356 A1 Jul. 4, 2002 Tuschl, et al. 435 69.1 Mar. 30, 2001 11. 6,423,489 B1 Jul. 23, 2002 Anderson, et al. 435 6 May 30, 1995 6,346,398 Feb. 12, 2002 Pavco, et al. 12. 6,355,415 Mar. 12, 2002 Wagner, et al. 13. Nov. 19, 2002 6,482,803 Ruth, et al. 14. 6,183,959 Feb. 6, 2001 Thompson 15. 6,225,291 May 1, 2001 Lewin, et al. 16. 6,245,560 June 12, 2001 Lisziewicz 17. 6,245,748 June 12, 2001 Wellstein, et al. 18. 6,255,071 July 3, 2001 Beach, et al. 19. 6,057,156 May 2, 2000 Akhtar, et al. 20.

Scheule, et al.

Duane, et al.

Pachuk, et al.

Falb

Hochberg, et al.

Veerapaneni, et al.

June 6, 2000

June 20, 2000

June 27, 2000

July 11, 2000

July 11, 2000

Aug. 8, 2000

6,071,890

6,077,705

6,080,851

6,087,164

6,087,172

6,099,823

21.

22.

23.

24.

25.

26.

	PATER	In Tako				·		
	27.	6,100,087	Aug. 8, 2000	Rossi, et al.				
	28.	6,100,444	Aug. 8, 2000	Frelinger, et al.				
	29.	6,107,094	Aug. 22, 2000	Crooke				
	30.	5,968,737	Nov. 16, 1999	Ali-Osman, et al.				
	31.	5,985,620	Nov. 16, 1999	Sioud				
	32.	5,908,779	June 1, 1999	Carmichael, et al.				
	33.	5,898,031	Apr 27, 1999	Crooke				
	34.	5,891,717	Apr. 6, 1999	Newgard, et al.		-		
	35.	5,866,701	Feb. 2, 1999	Hampel, et al.				
	36.	5,864,028	Jan. 26, 1999	Sioud				
,	37.	5,854,067	Dec. 29, 1998	Newgard, et al.				
	38.	5,814,500	Nov. 1998	Dietz				
	39.	5,811,300	Nov. 22, 1998	Sullivan, et al.				
	40.	5,811,275	Nov. 22, 1998	Wong-Staal, et al.				
	41.	5,837,510	Nov. 17, 1998	Goldsmith, et al.				
	42.	5,824,519	Oct. 20, 1998	Norris, et al				
	43.	5,712,257	Jan. 1998	Carter				
	44.	5,639,655	June 17, 1997	Thompson, et al.				
	45.	5,635,385	June 3, 1997	Leopold, et al.				
	46.	5,616,459	Apr. 1, 1997	Kramer, et al.				
	47.	5,574,142	Nov. 12. 1996	Meyer, Jr., et al.				
	48.	5,525,468	June 11, 1996	McSwiggen				
	49.	5,496,698	Mar. 5, 1996	Draper, et al.				
	50.	5,246,921	Sep. 21, 1993	Reddy, et al			, =	
	51.	5,225,347	July 6, 1993	Goldberg, et al.				
	52.	5,112,734	May 12, 1992	Kramer, et al.				
FOREIGI	N PATE	NT DOCUMENTS						
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translat	ion
			Date				YES	NO
	53.	DE 101 00 586 C1	April 11, 2002	Deutschland (Germany)	C12N	15/11		X
	54.	WO 03/080807 A2	Oct. 2, 2003	PCT	C12N		X	
	55.	WO 03/080794 A2	Oct. 2, 2003	PCT	C12N		X	

6	DE J	TOWN SELECTION OF THE PARTY OF	٠ .					
	PATENT 36.	WO 03/074654 A2	Sep. 12, 2003	PCT	C12N		X	
	57.	WO 03/070972 A2	Aug. 28, 2003	PCT	C12		X	
	58.	WO 03/070969 A2	Aug. 28, 2003	PCT	C12Q		X	
	59.	WO 03/070750 A2	Aug. 28, 2003	PCT	C07K		X	
	60.	WO 03/070283 A2	Aug. 28, 2003	PCT	A61K	48/00	X	
	61.	WO 03/016572 A1	Feb. 27, 2003	PCT	C12Q	1/68	X	
	62.	WO 03/012052 A2	Feb. 13, 2003	PCT	C12N		X	
	63.	WO 02/068637 A2	Sep. 6, 2002	PCT	C12N	15/11	X	
·	64.	WO 02/068635 A2	Sep. 6, 2002	PCT	C12N	15/11	X	
	65.	WO 02/44321 A2	Jun. 6, 2002	PCT	C12N		X	
	66.	WO 02/26780 A2	Apr. 4, 2002	PCT	C07K	14/00	X	
	67.	WO 01/75164 A2	Oct. 11, 2001	PCT	C12Q	1/68	X	
<u></u>	68.	WO 00/68374	Nov. 16, 2000	PCT	C12N	15/11	X	
	69.	WO 00/63364	Oct. 26, 2000	PCT				
	70.	WO 00/44895	Aug. 3, 2000	PCT	C12N	15/11		X
	71.	WO 00/44914	Aug. 3, 2000	PCT				
VA	72.	WO 00/01846	Jan. 13, 2000	PCT			•	
.,.	73.	WO 99/61631	Dec. 2, 1999	PCT				
	74.	WO99/53050	Oct. 21, 1999	PCT				
***	75.	WO 99/49029	Sept. 30, 1999	PCT		٠		
	76.	WO 99 32619	July 1, 1999	PCT				
	77.	WO 99/15682	Apr. 1, 1999	PCT				
	78.	WO 98/53083	Nov. 26, 1998	PCT				
	79.	DE 196 31 919 C2	July 1998	DE			X	
	80.	DE 196 18 797 C2	Nov. 13, 1997	DE				X
	81.	DE 196 18 797 A1	Oct. 1996	DE			X	
	82.	WO94/01550	Jan. 20, 1994	PCT				
OTHER I	OCUM	ENTS (including Auth	or, Title, Date, Pertin	nent Pages, etc.)		· · · · · · · · · · · · · · · · · · ·		
	83.	Agrawal et al., 1995	, 105-21, Editors: Al	chtar, Saghir, Publisher	CRC			
	84.	Ambros, V., (2001),	"Dicing Up RNAs",	Science, 293:811-813.				
	85.	Asanuma, H. et al., (1999), "Photoregulation der Bildung und Dissoziation eines DNA-Duplexes durch cis-trans-Isomerisierung einer Azobenzoleinheit", Angew. Chem., 111:2547-2549.						
	86.	Ausubel, F. et al. (19						

6	qi '	My was a second of the second
(2	) MAIN 1	
	Way	
	87.	Azhayeva, E. et al., (1997), "Inhibitory properties of double helix forming circular oligonucleotides", Nucl. Acids Res., 25:4954-4961.
	88.	Bahramian et al.; MOLECULAR AND CELLULAR BIOLOGY, Vol. 19:274 - 283, "Transcriptional and Posttranscriptional Silencing of Rodent α1(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene Jan. 1999
	89.	Barwkar, D.A. et al.; Proc. Natl. Acad. Sci USA, Vol. 95:11047 – 11052, September 1998, Chemistry, Biochemistry
	90.	Bass, B.L., (2000), "Double-Stranded RNA as a Template for Gene Silencing", Cell, 101:235-238.
	91.	Bhan et al., Nucleic Acid Research, 1997; Vol. 25; p. 3310
	92.	Billy, et al. (2001) PNAS 98(25):14428-33
	93.	Borecky et al. (1981-82) Tex Rep Biol Med 41:575-81 Abstract Only
·	94.	Castelli, J. et al., (998), "The 2-5A system in viral infection and apoptosis", <i>Biomed. Pharmacother.</i> , 52:386-390.
	95.	Cobaleda, C. et al., (2000), "In vivo inhibition by a site-specific catalytic RNA subunit of Rnase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment", <i>Blood</i> , 95(3):731-737.
	96.	Datenbank MEDLINE bei STN: AN 1999091059 MEDLINE; DN 99091059 zu: Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Kennerdell J.R.; Carthew R.W.; CELL, (1998 Dec. 23) 95(7):1017-1026.
	97.	Downward, J. et al., (1990), "Identification of a nucleotide exchange-promoting activity for p21 <sup>ras</sup> ", <i>Proc. Natl. Acad. Sci. USA</i> ", 87:5998-6002.
	98.	Elbashir, et al. (2001) Nature 411:494-498
	99.	Fire, 9/99, RNA-triggered gene silencing, Trends Genet, 15: 358-363.
	100.	Fire, A., et al., 1991, Production of Antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle, Development 113: 503-514
	101.	Gautschi, O. et al., (2001), "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins", <i>Journal of the National Cancer Institute</i> , 93(6):463-471.
	102.	Gibbs, J.B. et al., (1988), "Purification of ras GTPase activating protein from bovine brain", <i>Proc. Natl. Acad. Sci. USA</i> ", 85:5026-5030.
	103.	Grasby, JA et al.; Biochemistry 1995 Mar 28; 34(12);4068 – 76
	104.	Griffey, RH et al.; J Med Chem 1996 Dec 20; 39(26);5100-9
	105.	Ha, I et al.; Genes Dev 1996 Dec 1;10(23);3041-50
	106.	Hamilton et al.; SCIENCE, Vol. 286:950 - 951, "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants (Oct. 29, 1999)
	107.	Hammond, S.M. et al., (2000), "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells", <i>Nature</i> , 404:293-296.
	108.	Hoke, GD et al.; Nucleic Acids Res 1991 Oct 25; 19(20):5743-8



 109.	Holen, T. et al., (2002), "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor", <i>Nucleic Acids Research</i> , 30(8):1757-1766.
110.	Horn, T et al.; Nucleic Acids Research, 1997, Vol. 25, No. 23 : 4842 – 4849
111.	Hunter, 6/17/99, A touch of elegance with RNAi, Curr Biolo, 9: R440-R442
112.	Iwase, R et al.; Nucleic Acids Symp Ser 1997; (37);203 – 4
113.	Jacobs, B.L., and Langland, J.O., 1996, When two stands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology 219: 339-349
114.	Kennerdell et al.; CELL, Vol. 95, S. 1017 – 1026; "Use of dsRNA-Mediated Genetic Interference to Demonstrate that frizzled and frizzled 2 Act in the Wingless Pathway" Dec 23, 1998
115.	Klemens, et al.(1999), The 2 Å Structure of helix 6 of the human signal recognition particle RNA., Structure 7(11): 1345-1352
116.	Kreutzer et al (1999) Gesellschaft fur Biochemie und Molekularbiologie S169
117.	Lee, et al.; CELL, Vol. 88; S. 637 – 646; March 7, 1997; "The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA
118.	Li et al., Dev. Biology Volume 210, 1999, p. 238 abstract 346
119.	Lin et al.; NATURE, Vol. 402:128 - 129, "Policing rogue genes" Nov. 11, 1999
 120.	Lipardi, C. et al., (2001), "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs", <i>Cell</i> , 107:297-307.
 121.	Lipinski, et al. (1997) Adv. Drug Delivery Review 23:3-25
 122.	Lowy, D.R. et al., (1993), "Function and Regulation of RAS", Annu. Rev. Biochem., 62:851-891.
 123.	Ma MY (1993) Biochem. 32(7):1751-8
 124.	Majumdar, A et al.; Nat Genet 1998 Oct; 20(2):212-4
 125.	Milhaud et al., Journal of Interferon Research, 1991, vol. 11, 261-265
 126.	Minks, M. A. et al., The Journal of Biological Chemistry (1979), 254, (20):10180 – 10183
127.	Montgomery, M., and Fire, 1998, Analysis of a Caenorhabditis elegans twist homolog identifies conserved and divergent aspects of mesodermal patterning, Genes and Development, 12: 2623-2635.
128.	Montgomery M.K., et al., 1998, RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegan, Proc. Natl. Acad. Sci. 95: 15502-15507.
129.	Montgomery, et al., July 1998, Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression, TIG, Vol. 14, No. 7., pgs. 255-258
130.	Misquitta, L. and Paterson, B.M., 1999, Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic somatic muscle formation, Proc. Natl. Acad. Sci. 96: 1451-1456
 131.	Neilsen et al. (1997) Chem. Comm. 825-826
 132.	Ngo, H., et al., 1998, Double-stranded RNA induces mRNA degradation in Trypanosoma brucei, Proc. Natl. Acad. Sci. 95: 14687-14692.
133.	Nikiforov, et al. (1992) Nucleic Acids Research 20(6):1209-1214